Viatris stock slides 24% as analysts say sale of biosimilars to Indian partner removes key growth driver

Viatris Inc. said Monday it has agreed to combine its biosimilars portfolio with privately held Indian company Biocon Biologics Ltd. for up to $3.335 billion, as part of a broader overhaul of its busi...

Viatris to Sell Biosimilars Business for $3 Billion. Shares Tumble.

Viatris will sell the biosimilars business of the former Mylan to the Indian drugmaker Biocon for as much as $3.3 billion. Dreamstime Text size Viatris , the company formed in 2020 through a merger of...

Covid-19 Vaccine Makers Face a New Rival as GlaxoSmithKline and Sanofi Prepare to Enter the Ring

As new Covid-19 cases fall, the postpandemic vaccine market grows more interesting. On Wednesday, GlaxoSmithKline and Sanofi, two of the world’s largest vaccine makers, said they would submit a Covid ...

Pfizer Becomes Oversold

The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important ...

Pfizer Stock Is Falling. Did Investors Misunderstand the Revenue Guidance?

Pfizer CEO Albert Bourla talks. John Thys/Pool/AFP/Getty Images Text size Pfizer shares dropped sharply after the company’s 2022 sales guidance appeared to fall short of expectations. The guidance tha...

Pfizer Stock Fell 2.8%. Did Investors Misunderstand the Revenue Guidance?

Text size Pfizer CEO Albert Bourla talks. John Thys/Pool/AFP/Getty Images Pfizer shares dropped sharply on Tuesday after the company’s 2022 sales guidance appeared to fall short of expectations. The g...

Novavax Stock Tumbles on Report That Vaccine Deliveries Are Lagging

Text size Novavax labs in Gaithersburg, Md. Andrew Caballero-Reynolds/AFP via Getty Images Novavax shares were plunging more than 15% Tuesday after the company acknowledged to Reuters that it has comp...

Pfizer (PFE) earnings Q4 2021

Pfizer CEO Albert Bourla addresses a press conference after a visit to oversee the production of the Pfizer-BioNtech COVID-19 vaccine at the factory of U.S. pharmaceutical company Pfizer in Puurs, Bel...

Pfizer stock falls after profit beats but revenue misses, even as COVID-19 vaccine sales of $12.5 billion top forecasts

Shares of Pfizer Inc. PFE, +0.40% sank 2.6% in premarket trading Tuesday, after the drug maker reported fourth-quarter profit that beat expectations, while revenue more than doubled but missed forecas...

Pfizer Reports Earnings Tuesday. What to Expect.

Text size Pfizer is scheduled to report its earnings before the market opens on Tuesday. Jeenah Moon/Getty Images There’s no mystery about what 2022 will bring for Pfizer : Enormous, record-shattering...

Moderna Faces Challenges Beyond the Covid Vaccine. Its Stock Is Still a Buy for the Long Term.

In 2019, four pharmaceutical giants shared virtually all of the $33 billion worth of vaccine revenue earned worldwide. The pandemic has upended the vaccine business. Moderna has sold or contracted to ...

It’s Time to Bargain Hunt. 27 Picks to Beat the Stock Market From Barron’s Roundtable Experts.

“There is no easier way to make money in the market than to buy a great company under pressure due to short-term concerns.” So said the newest member of the Barron’s Roundtable, David Giroux of T. Row...

Johnson & Johnson’s got a new CEO and a plan to split the company in two. Here’s what else to expect out of J&J’s earnings

Johnson & Johnson JNJ, -0.31% has long been viewed as a bellwether stock for other health care companies, given its early slot in the earnings calendar and a business model that spans everything f...

Moderna and Novavax Stocks Get Whacked by Supreme Court’s Vaccine Decision

Text size A nurse takes a Moderna Covid-19 vaccines ready to be administered at a vaccination site Apu Gomes/AFP via Getty Images Novavax stock and shares of other vaccine makers fell Friday after the...

Opinion: Value has beaten growth by a huge margin — these are now top investment newsletters’ best value-stock picks

(Note: The dividend-yield column at the bottom of this story has been corrected. The correct yields are now shown.) Value will be especially valuable in 2022. I’m referring to the latest round in valu...